Marcia Sistek, MD
Family Medicine · Scottsdale, AZNPI 1477543486
Payments from drug & device makers
Across 237 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$818
- Amneal Pharmaceuticals LLC$372
- Lilly USA, LLC$275
- Pfizer$249
- Boehringer Ingelheim$182
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,529100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $1,241 |
| AbbVie(2 entities) | 50 | $818 |
| Amneal Pharmaceuticals LLC | 22 | $372 |
| Lilly USA, LLC | 18 | $275 |
| Pfizer | 15 | $249 |
| Boehringer Ingelheim | 11 | $182 |
| GSK | 11 | $182 |
| Johnson & Johnson | 8 | $146 |
| Amgen | 7 | $135 |
| Biohaven Pharmaceuticals, Inc. | 7 | $124 |
| Sanofi Pasteur Inc. | 6 | $118 |
| Abbott | 5 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $89 |
| Exact Sciences | 3 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Merck | 3 | $48 |
| Novo Nordisk | 3 | $47 |
| Therapeuticsmd, Inc. | 2 | $37 |
| Alfasigma USA, Inc. | 2 | $34 |
| Saluda Medical Americas, Inc. | 1 | $32 |
| Averitas Pharma Inc. | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Nevro Corp. | 1 | $21 |
| Seqirus USA Inc | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,529 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 29 | $25,924 |
| MounjaroTirzepatide | 21 | $24,038 |
| FarxigaDapagliflozin Propanediol | 15 | $23,749 |
| JanuviaSitagliptin Phosphate | 21 | $23,734 |
| OzempicSemaglutide | 23 | $22,023 |
| JardianceEmpagliflozin | 15 | $12,325 |
| XareltoRivaroxaban | 11 | $11,409 |
| SynthroidLevothyroxine Sodium | 79 | $9,676 |
| UnithroidLevothyroxine Sodium | 52 | $3,668 |
| Raloxifene Hcl | 63 | $2,633 |
| LevoxylLevothyroxine Sodium | 43 | $2,373 |
| Oxazepam | 12 | $2,351 |
| Rosuvastatin Calcium | 191 | $1,585 |
| Levothyroxine Sodium | 202 | $1,291 |
| Eszopiclone | 51 | $1,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $275 | $49,96250 claims |
| AstraZenecaFarxiga | $1,241 | $23,74915 claims |
| MerckJanuvia | $48 | $23,73421 claims |
| Novo NordiskOzempic | $47 | $22,02323 claims |
| Boehringer IngelheimJardiance | $182 | $12,32515 claims |
| Johnson & JohnsonXarelto | $146 | $11,40911 claims |
| AbbVieSynthroid | $818 | $9,67679 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $372 | $4,960254 claims |
| PfizerLevoxyl | $249 | $2,37343 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Scottsdale
- Danielle ArmasScottsdale$73M
- Joseph LilloScottsdale$6.3M
- Sam FereidouniScottsdale$486K
- Casey MyersScottsdale$246K
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.